- Acquired by Zmiha Investment House Ltd. for $3.2M, Sep 2013
- Raised $30M Series C led by Lewis Pell, Jan 2010
- Raised $29M Series B led by Concord Ventures, May 2005
About
Proteologics Ltd is a biopharmaceutical company exploiting the ubiquitin system for the discovery and development of novel therapeuticsforcancer treatment. The reserach was performed byidentifying correlations between ubiquitin pathway components and pathological conditions. The ubiquitin system was discovered by two Israeli Nobel Prize Laureates, Avram Hershko and Aaron Ciechanover. Proteologics hasexploited the ubiquitin system for the novel therapeutics,focusing primarily on discovering inhibitors for specific E3 ubiquitin ligases. In 2012, XTLBiopharmaceuticals Ltd. (Pink Sheets:XTLBY; TASE:XTL) acquired 31% stake in Proteologics. Until then,Teva Pharmaceutical Industries Ltd. was the controlling shareholder in Proteologics. In Sept. 2013, Zmiha Investment House Ltd. (TASE: TZMI) has acquired control of Proteologics Ltd. from XTL Biopharmaceuticals Ltd. for NIS 12.1 million, including the control premium. Zmiha, a licensee in the Yam 3 offshore oil and gas exploration license, bought 6,738,828 Proteologics shares, 44.95% of the company. At that point, Proteologicsdecided to freeze its research activity. However, itsStocks have been tradedontheTASE. In addition, Proteologicshas several initial joint-development agreements with big pharma companies.
Funding history · 4 rounds · $82.5M total
Headcount over time
Offices
Q&A
- What is Proteologics' primary focus in biopharmaceutical research?
- Proteologics is a biopharmaceutical company that exploits the ubiquitin system for the discovery and development of novel therapeutics, primarily focusing on discovering inhibitors for specific E3 ubiquitin ligases for cancer treatment.
- When was Proteologics founded?
- Proteologics was founded in May 1999.
- What was the initial significant acquisition of a stake in Proteologics?
- In 2012, XTL Biopharmaceuticals Ltd. acquired a 31% stake in Proteologics. Prior to this, Teva Pharmaceutical Industries Ltd. was the controlling shareholder.
- Who acquired control of Proteologics in September 2013 and for what amount?
- In September 2013, Zmiha Investment House Ltd. acquired control of Proteologics Ltd. from XTL Biopharmaceuticals Ltd. for NIS 12.1 million, including the control premium.
- What was the immediate consequence of Zmiha Investment House Ltd.'s acquisition of Proteologics?
- Following the acquisition by Zmiha Investment House Ltd. in September 2013, Proteologics decided to freeze its research activity.
- How many employees does Proteologics have?
- Proteologics has 1-10 employees.
- What is the total amount of funding Proteologics has raised?
- Proteologics has raised a total of $25,000,000 USD.
- Does Proteologics hold any patents?
- Yes, Proteologics holds 1 patent.
Team · 7
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/129024 |
Identifiers & details
| Legal name | Proteologics Ltd. |
|---|---|
| Founded | 1999-5 |
| Employees (exact) | 6 |
| Status reason | Acquired (Inactive) by Zmiha Investment House Ltd. on Sep 2013 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Zmiha Investment House Ltd. 2013-09 $3.2M
Radar intelligence
Patents
| EPO | 40 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512781386 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1999-05-19 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2010 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | דרך בגין 55 תל אביב - יפו |